Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular

M Kyriakidis1, A Antonopoulos, E Georgiou

  • 1Department of Cardiology, Hippokration Hospital, University of Athens, Greece.

Insights

Captopril improves cardiac performance in post-myocardial infarction patients with reduced ejection fraction. This study shows captopril, combined with standard therapy, enhances left ventricular function response to increased afterload, particularly in those with ejection fraction < 40%.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme inhibitors (ACEIs) show benefits in acute myocardial infarction (AMI).
  • Limited data exist on ACEIs' effects on cardiac performance under increased afterload in AMI patients.

Purpose of the Study:

  • To investigate the effects of captopril as adjuvant therapy on left ventricular performance in Q-wave AMI patients.
  • To assess the impact of increased afterload on cardiac function in AMI patients treated with standard therapy versus captopril.

Main Methods:

  • 77 consecutive Q-wave AMI patients were studied.
  • Phenylephrine was administered to measure pre-ejection period/left ventricular ejection time ratio (PEP/LVET) on days 4 and 30.
  • Patients were randomized to standard therapy alone or with captopril.

Main Results:

  • Standard therapy alone led to significant left ventricular dysfunction after phenylephrine in patients with ejection fraction < 40%.
  • Captopril adjuvant therapy improved PEP/LVET ratio between days 4 and 30 in patients with ejection fraction < 40%.
  • No significant benefit was observed in patients with ejection fraction >= 40%.

Conclusions:

  • PEP/LVET ratio response to increased afterload is a useful non-invasive marker for left ventricular dysfunction post-MI.
  • Captopril adjuvant therapy improves left ventricular performance and heart rate response in asymptomatic Q-wave post-MI patients, especially those with ejection fraction < 40%.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.